Intravenous Busulfan and Melphalan, Tacrolimus, and Short-Course Methotrexate Followed by Unmodified HLA-Matched Related or Unrelated Hematopoietic Stem.

Slides:

Advertisements

Similar presentations

Evidence of B Cell Immune Responses to Acute Lymphoblastic Leukemia in Murine Allogeneic Hematopoietic Stem Cell Transplantation Recipients Treated with.

Advertisements

Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Adults with Relapsed and Refractory Mantle Cell Lymphoma: A Single Center Retrospective.

The Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes.

How to Treat MDS without Stem Cell Transplantation

Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies Marcelo C. Pasquini,

Low Dose Unfractionated Heparin (UFH) Prophylaxis Is a Feasible Strategy for the Prevention of Hepatic Sinusoidal Obstruction Syndrome (SOS) after Myeloablative.

Fludarabine-Based Conditioning Secures Engraftment of Second Hematopoietic Stem Cell Allografts (HSCT) in the Treatment of Initial Graft Failure Joseph.

Vaccination of Children following Allogeneic Stem Cell Transplantation

T Cell–Depleted Stem Cell Transplantation for Adults with High-Risk Acute Lymphoblastic Leukemia: Long-Term Survival for Patients in First Complete Remission.

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes

Challenges and Potential Solutions for Recruitment and Retention of Hematopoietic Cell Transplantation Physicians: The National Marrow Donor Program’s.

Allogeneic Stem Cell Transplantation in Myelofibrosis

A Novel Reduced-Intensity Conditioning Regimen Induces a High Incidence of Sustained Donor-Derived Neutrophil and Platelet Engraftment after Double-Unit.

Hematologic Safety Profile of Linezolid in the Early Periengraftment Period after Allogeneic Stem Cell Transplantation Nina Cohen, Coralia N. Mihu, Susan.

Response to Pneumococcal (PNCRM7) and Haemophilus Influenzae Conjugate Vaccines (HIB) in Pediatric and Adult Recipients of an Allogeneic Hematopoietic.

Immune-Mediated Hemolytic Anemia (IMHA) and Immune Thrombocytopenia (ITP) after Ex-Vivo CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation

Major ABO Blood Group Mismatch Increases the Risk for Graft Failure after Unrelated Donor Hematopoietic Stem Cell Transplantation Mats Remberger, Emma.

Outcomes of Patients with Myeloid Malignancies Treated with Allogeneic Hematopoietic Stem Cell Transplantation from Matched Unrelated Donors Compared.

Combining the Disease Risk Index (DRI) and Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Provides a Comprehensive Prognostic Model for.

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Edward Copelan, James T. Casper, Shelly L. Carter, Jo-Anne H

High Disease-Free Survival (DFS) Supports Continued Investigation of Double-Unit Cord Blood Transplantation (DCBT) in Children with High-Risk Acute Leukemia.

Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients with Hematologic Malignancies Using Busulfan, Fludarabine,

Sabina Kersting, Leo F. Verdonck

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Frequent Human Herpesvirus-6 Viremia But Low Incidence of Encephalitis in Double- Unit Cord Blood Recipients Transplanted Without Antithymocyte Globulin

Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord.

The Role of Post-Remission Chemotherapy before T-Cell Depleted Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia in First Complete Remission

Phase I Study of Clofarabine and 2-Gy Total Body Irradiation as a Nonmyeloablative Preparative Regimen for Hematopoietic Stem Cell Transplantation in.

Twenty Years of Unrelated Donor Bone Marrow Transplantation for Pediatric Acute Leukemia Facilitated by the National Marrow Donor Program Margaret L.

Dynamic Detection of Anti–Human Leukocyte Antigen (HLA) Antibodies but not HLA-DP Loci Mismatches Can Predict Acute Graft-versus-Host Disease and Overall.

Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation Lindsay G. Jensen, Tracey Stiller,

Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma:

Availability of Cord Blood Extends Allogeneic Hematopoietic Stem Cell Transplant Access to Racial and Ethnic Minorities Juliet N. Barker, Courtney E.

Infections Are the Major Cause of Non Relapse Mortality (NRM) after T Cell Depleted (TCD) Allogeneic Hematopoietic Stem Cell Transplantation for Advanced.

Graft-Versus Host Disease (GVHD Status and Severity Mediate Late Effects of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in a 1-Year Landmark.

Long-Term Prognosis Among 1-Year Survivors of Ex Vivo T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation: A Landmark Analysis Christina.

Single Cord Blood Combined with HLA-Mismatched Third Party Donor Cells: Comparable Results to Matched Unrelated Donor Transplantation in High-Risk Patients.

Cardiovascular Risk Factors in Survivors of Childhood Hematopoietic Cell Transplantation Treated with Total Body Irradiation: A Longitudinal Analysis

Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation Has Unique Features and an Association with Engrafting Unit-to-Recipient HLA Match

Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma John Kuruvilla, Gregory Pond, Richard.

Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Disparity in Survival Outcome after Hematopoietic Stem Cell Transplantation for Hematologic Malignancies According to Area of Primary Residence Keshav.

Human Parainfluenza Virus Infection after Hematopoietic Stem Cell Transplantation: Risk Factors, Management, Mortality, and Changes over Time Celalettin.

Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis Jason.

Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa Barbara.

Impact of Donor and Recipient Cytomegalovirus Serostatus on Outcomes of Antithymocyte Globulin–Conditioned Hematopoietic Cell Transplantation Amit Kalra,

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Allogeneic Hematopoietic Stem Cell Transplantation Is Underutilized in Older Patients with Myelodysplastic Syndromes Bartlomiej M. Getta, Ashwin Kishtagari,

Gerard Socié, K. Scott Baker, Smita Bhatia

What is quality in a transplant program?

Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution William B. Ershler, Andrew S. Artz, Evan T. Keller

CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50.

Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving.

Karen K. Ballen, Roberta J. King, Pintip Chitphakdithai, Charles D

Haploidentical Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for Treatment of Hematologic Malignancies in Children Xiaojun.

Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match Jason Dehn, Mukta Arora, Stephen Spellman, Michelle Setterholm,

Blood and Marrow Transplant Handbook

Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.

T Cell–Depleted Related HLA-Mismatched Peripheral Blood Stem Cell Transplantation as Salvage Therapy for Graft Failure after Single Unit Unrelated Donor.

A Meta-analysis of Patients Receiving Allogeneic or Autologous Hematopoietic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome Peggy A. Wu,

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Cytomegalovirus Infection after CD34+-Selected Hematopoietic Cell Transplantation Yao-Ting Huang, Dionysios Neofytos, Julia Foldi, Seong Jin Kim, Molly.

Mammen Chandy Biology of Blood and Marrow Transplantation

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Treatment versus Transplant for Challenging Hematologic Disorders

Early Fluid Overload is a Serious Toxicity Associated with an Increased Risk of Non- Relapse Mortality after Ex-Vivo CD34-Selected Allogeneic Hematopoietic.

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

Reduced Late Mortality Risk Contributes to Similar Survival after Double-Unit Cord Blood Transplantation Compared with Related and Unrelated Donor Hematopoietic.

Presentation transcript:

Intravenous Busulfan and Melphalan, Tacrolimus, and Short-Course Methotrexate Followed by Unmodified HLA-Matched Related or Unrelated Hematopoietic Stem Cell Transplantation for the Treatment of Advanced Hematologic Malignancies Trudy N. Small, James W. Young, Hugo Castro-Malaspina, Susan Prockop, Andrew Wilton, Glenn Heller, Farid Boulad, Michelle Chiu, Katherine Hsu, Ann Jakubowski, Nancy A. Kernan, Miguel-Angel Perales, Richard J. O’Reilly, Esperanza B. Papadopoulos Biology of Blood and Marrow Transplantation Volume 13, Issue 2, Pages 235-244 (February 2007) DOI: 10.1016/j.bbmt.2006.10.005 Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Cumulative incidence of recurrence. Biology of Blood and Marrow Transplantation 2007 13, 235-244DOI: (10.1016/j.bbmt.2006.10.005) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 (A) OS and DFS (n = 43). (B) OS and DFS by blast count ≤ 20% or > 20%. Biology of Blood and Marrow Transplantation 2007 13, 235-244DOI: (10.1016/j.bbmt.2006.10.005) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 OS (upper) and DFS (lower) in the 38 patients with a myeloid malignancy. Biology of Blood and Marrow Transplantation 2007 13, 235-244DOI: (10.1016/j.bbmt.2006.10.005) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Nonleukemic mortality. Biology of Blood and Marrow Transplantation 2007 13, 235-244DOI: (10.1016/j.bbmt.2006.10.005) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions